Literature DB >> 35477536

Covid-19: What is the evidence for the antiviral Paxlovid?

Andy Extance1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35477536     DOI： 10.1136/bmj.o1037

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2.

Authors:  Jinyuan Li; Shuzhao Chen; Yang Li; Ziang Zhu; Hanying Huang; Weida Wang; Yao Yang; Yang Liang; Lingling Shu
Journal:  Front Genet       Date:  2022-06-17       Impact factor: 4.772

2.  De Novo design of potential inhibitors against SARS-CoV-2 Mpro.

Authors:  Shimeng Li; Lianxin Wang; Jinhui Meng; Qi Zhao; Li Zhang; Hongsheng Liu
Journal:  Comput Biol Med       Date:  2022-06-15       Impact factor: 6.698

Review 3.  Virus Infection and Systemic Inflammation: Lessons Learnt from COVID-19 and Beyond.

Authors:  Aileen Faist; Josua Janowski; Sriram Kumar; Saskia Hinse; Duygu Merve Çalışkan; Julius Lange; Stephan Ludwig; Linda Brunotte
Journal:  Cells       Date:  2022-07-14       Impact factor: 7.666

4.  Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic.

Authors:  Giulia Garzi; Francesco Cinetto; Davide Firinu; Giulia Di Napoli; Gianluca Lagnese; Alessandra Punziano; Patrick Bez; Bianca Laura Cinicola; Giulia Costanzo; Riccardo Scarpa; Federica Pulvirenti; Marcello Rattazzi; Giuseppe Spadaro; Isabella Quinti; Cinzia Milito
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.